Prior results with the drug in other surgical settings have been mixed ...

P.S.S. Urology, Inc. ('P.S.S. Urology”), a next-generation U.S. medical device distributor delivering clinically proven, cost ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

The PAUSE-URO study evaluated the safety of a new protocol for patients using direct oral anticoagulants (DOACs) prior to elective urologic surgery.

Spokane Valley, WA, March 17, 2026 (GLOBE NEWSWIRE)-- P.S.S. Urology, Inc. (“P.S.S. Urology”), a next-generation U.S. medical device distributor delivering clinically proven, cost-efficient solutions ...

With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...

Intuitive Surgical is recalling one set of its stapler reloads used by its da Vinci robot after incomplete deliveries failed to properly close blood vessels during procedures.  | This comes in the ...

The recall follows reports of incomplete staple lines in procedures using the company’s da Vinci surgical robots.

The FDA today issued an early alert related to an issue with a surgical stapler reload made by Intuitive Surgical (Nasdaq: ...

It can feel like everything is a cancer risk these days, even items that used to be considered "good" for our overall health (we see you, red wine). However, it goes without saying that "cancer" is a ...